San Diego-dependent Viking Therapeutics marked alone as a significant competitor inside the weight loss drug market in February following revealing promising details from the mid-phase demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when offered as being a weekly injection As well as in March